Lechleiter: German drug pricing creates ‘uncertainty’ for Lilly

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and didn’t include enough input from the pharmaceutical industry.

Following a price freeze and an increase in mandatory rebates, Lechleiter told government officials last week the new policy, which determines the price of a new drug based on benefit, creates “uncertainty” for the company’s business planning, he said.

“We discover and develop medicines because we think that when they get to the market, they’re going to make a difference,” he said. “We often don’t know that until they’ve been used for a while, until physicians and patients begin to experience medicines in the real world.”

Lilly is interested in the animal-health industry and wants to expand this business further, Lechleiter also said in an interview in Frankfurt on Monday. He declined to comment specifically on Pfizer Inc.’s plan to sell or spin off its veterinary business.

“You have to assume that we’re looking at everything in the space,” he said.

The company will consider partnerships in neuroscience, cancer and diabetes research, Lechleiter said.

Lilly still plans to double sales in emerging markets between 2010 and 2015, largely by organic growth, particularly in China, he said. Lilly faces increased generic competition over the next three years that is expected to reduce annual sales by $7 billion between 2010 and 2014, the company said in June.

With “animal health and the emerging markets, where there is a compelling business case, we’re going to continue to be thoughtful and sometimes aggressive as the case may dictate,” Lechleiter said.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In